Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

OBJECTIVE: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double‐stranded DN...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arthritis Rheumatol
Asıl Yazarlar: Doria, A., Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., van Vollenhoven, R., Hammer, A. E., Groark, J., Bass, D., Fox, N. L., Roth, D., Gordon, D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Systemic Lupus Erythematosus
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6099508/
https://ncbi.nlm.nih.gov/pubmed/29671280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40511
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller